NGS white paper landing page image

Nucleic acids are the building blocks for many advanced therapy products and are a critical part to the evolution of next generation medicines. The criticality to ensure that these products are manufactured and tested right the first time drives the success, safety and time to market for these medicines. New technologies and advances made in sequencing capabilities allow for the success criteria in the current global regulatory landscape.

Nucleic acids, such as plasmids and mRNA are crucial for the generation of vaccines and cell and gene therapies. The global market for plasmid DNA manufacturing reached an estimated $1.80 billion in 2023 and is expected to grow at a rate of 21% over the next 7 years. Of the grade of material being produced, good manufacturing practice (GMP) grade plasmids dominated the market due to the surge in clinical development of new cell and gene therapies. Also adding to demand is the development of plasmid-DNA vaccines due to their low risk of oncogenesis and immunogenicity. SK pharmteco is uniquely positioned to manufacture GMP plasmids at large scale along with a comprehensive panel of analytical methods to guarantee identity of the product being produced.

Complete the form below to read more about this exciting topic!

Download Next Generation Analytical Testing Sequencing, Solutions for Nucleic Acids and Advanced Therapy Products white paper

"*" indicates required fields

Privacy Policy*
Newsletter subscription
This field is for validation purposes and should be left unchanged.

Scroll to Top

Enter your details to access Marketing Materials